FEMY - Femasys commercially launches Femcerv for cervical cancer screening

• Femasys ( NASDAQ: FEMY ) said its endocervical tissue sampler, FemCerv, was commercially available now.
• The Company also appointed Michael Meier as Vice President of Sales and Marketing.
• FemCerv is used to capture and protect a comprehensive 360-degree tissue sample.
• When a woman’s pap smear is abnormal, she generally needs to undergo a colposcopy, which includes endocervical curettage or taking a tissue sample.
• Meier experience will be invaluable in overseeing Femasys commercial assets, including FemCerv’s availability and commercial-readiness of subsequent products in line, the company said.

For further details see: